Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Johnson & Johnson Share Price

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 08:20:00 06/12/2024 pm IST 		5-day change 1st Jan Change
149.54 USD +0.01% Intraday chart for Johnson & Johnson -3.49% -4.56%
05/12 J&J: classification system for surgical complications CF
02/12 J&J: applies to the FDA for Tremfya in pediatrics CF

Valuation: Johnson & Johnson

Capitalization 36TCr 34TCr 32TCr 28TCr 51TCr 30,49700Cr 56TCr 3,91500Cr 1,45200Cr 12,49300Cr 1,35100Cr 1,32200Cr 54,05100Cr P/E ratio 2024 *
21.8x
P/E ratio 2025 * 17.1x
Enterprise value 37TCr 35TCr 33TCr 29TCr 52TCr 31,49700Cr 58TCr 4,04300Cr 1,50000Cr 12,90300Cr 1,39500Cr 1,36600Cr 55,82300Cr EV / Sales 2024 *
4.19x
EV / Sales 2025 * 3.9x
Free-Float
77.09%
Yield 2024 *
3.26%
Yield 2025 * 3.41%
More valuation ratios * Estimated data

Chart: Johnson & Johnson

Dynamic Chart

Latest news: Johnson & Johnson

J&J: classification system for surgical complications 05/12 CF
J&J: applies to the FDA for Tremfya in pediatrics 02/12 CF
J&J: FDA green light for MemoryGel breast implants 02/12 CF
Johnson & Johnson Seeks FDA Approval of Tremfya in Children 02/12 MT
Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA 02/12 CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List 29/11 MT
Sanofi plans to change hospital drug-discount program, WSJ reports 22/11 RE
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis 22/11 MT
Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya inulcerative Colitis, A First for an IL-23 Inhibitor 22/11 CI
Johnson & Johnson Announces Health Canada Authorizes CARVYKTI for Patients with Relapsed or Refractory Multiple Myeloma Who Receive One to Three Prior Lines of Therapy 22/11 CI
Johnson & Johnson, Merck Cut Jobs in China 21/11 MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon 21/11 MT
Johnson & Johnson, Merck Cut Jobs in China 20/11 MT
More news

Last Transcript: Johnson & Johnson

Logo Johnson & Johnson
Johnson & Johnson Presents at Stifel 2024 Healthcare Conference, Nov-18-2024 10:55 AM
18/11
More transcripts

Analysts' recommendations: Johnson & Johnson

J&J: positive CHMP opinion for Lazcluze in lung cancer 18/11 CF
Wolfe Research Initiates Johnson & Johnson at Outperform With $190 Price Target 15/11 MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating 06/11 MT
Daiwa Securities Adjusts Price Target on Johnson & Johnson to $170 From $150, Maintains Neutral Rating 22/10 MT
Argus Adjusts Price Target on Johnson & Johnson to $185 From $180 17/10 MT
More recommendations

Press Releases: Johnson & Johnson

Johnson & Johnson : MedTech Joins Experts to Define and Classify Surgical Site Outcomes 05/12 PU
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA 03/12 AQ
PBM Contracting And Administration: What Are The Rules Of The Road For Self-Insured Employees? 03/12 AQ
Johnson & Johnson : MENTOR™ MemoryGel™ Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction 03/12 PU
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) 02/12 PR
More press releases

News in other languages: Johnson & Johnson

J&J : système de classification de complications chirurgicales 05/12
J&J : sollicite la FDA pour Tremfya en pédiatrie 02/12
J&J : feu vert de la FDA pour les implants mammaires MemoryGel 02/12
Nvidia, peut mieux faire 21/11
En Direct des Marchés : Nvidia déçoit ses fans, STMicro et Soitec s'agitent 21/11
More news

Quotes and Performance

1 day+0.83%
1 week-3.78%
Current month-3.54%
1 month-5.58%
3 months-9.38%
6 months+2.43%
Current year-4.61%
More quotes

Course Extremes

1 week
148.95
Extreme 148.95
155.00
1 month
148.95
Extreme 148.95
158.75
Current year
143.13
Extreme 143.13
168.85
1 year
143.13
Extreme 143.13
168.85
3 years
143.13
Extreme 143.13
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes

Managers and Directors: Johnson & Johnson

Director TitleAgeSince
Joaquin Duato CEO
 Chief Executive Officer 61 03/01/2022
Joseph Wolk DFI
 Director of Finance/CFO 57 01/07/2018
William Hait CTO
 Chief Tech/Sci/R&D Officer 74 01/01/2022
Manager TitleAgeSince
Anne Mulcahy BRD
 Director/Board Member 71 23/10/2009
Mark McClellan BRD
 Director/Board Member 60 15/10/2013
Mary Beckerle BRD
 Director/Board Member 69 09/06/2015
More insiders

ETFs: Johnson & Johnson

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.01% 380 M€ +10.15% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
12.91% 20 M€ +16.75% -
More ETFs: Johnson & Johnson

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.63%-3.78%-5.70%-6.19%36TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.51%+4.75%+40.38%+236.19%74TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.15%+3.13%+12.21%+118.94%48TCr
ABBVIE INC. Stock AbbVie Inc.
-0.16%-3.77%+21.86%+48.23%31TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+2.15%+0.42%-2.52%+41.19%26TCr
ROCHE HOLDING AG Stock Roche Holding AG
+1.02%+0.95%+2.13%-29.25%23TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+1.32%+0.23%+4.67%+29.63%21TCr
NOVARTIS AG Stock Novartis AG
+0.31%-3.21%+6.25%+22.85%21TCr
AMGEN INC. Stock Amgen Inc.
-1.41%-2.05%+1.28%+35.51%15TCr
PFIZER, INC. Stock Pfizer, Inc.
+1.86%-0.50%-11.65%-52.64%15TCr
Average +0.03%-0.24%+6.89%+44.45% 31.03TCr
Weighted average by Cap. -0.08%+0.66%+13.30%+83.25%
See all sector performances

Financials

2024 *2025 *
Net sales 8.88TCr 8.4TCr 7.81TCr 6.96TCr 12TCr 7,52200Cr 14TCr 97TCr 36TCr 3,08100Cr 33TCr 33TCr 13,33100Cr 9.13TCr 8.64TCr 8.03TCr 7.16TCr 13TCr 7,73700Cr 14TCr 99TCr 37TCr 3,17000Cr 34TCr 34TCr 13,71300Cr
Net income 1.75TCr 1.66TCr 1.54TCr 1.37TCr 2.46TCr 1,48200Cr 2.72TCr 19TCr 7.06TCr 61TCr 6.57TCr 6.43TCr 2,62700Cr 2.08TCr 1.96TCr 1.83TCr 1.63TCr 2.91TCr 1,75900Cr 3.22TCr 23TCr 8.37TCr 72TCr 7.79TCr 7.63TCr 3,11700Cr
Net Debt 1.18TCr 1.12TCr 1.04TCr 925.39Cr 1.66TCr 1,00000Cr 1.83TCr 13TCr 4.76TCr 41TCr 4.43TCr 4.34TCr 1,77200Cr -354.59Cr -335.47Cr -311.77Cr -277.98Cr -497.47Cr -30TCr -550.67Cr -3.86TCr -1.43TCr -12TCr -1.33TCr -1.3TCr -53TCr
More financial data * Estimated data

Company Profile

Logo Johnson & Johnson
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.3%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.7%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2023, Johnson & Johnson has 61 manufacturing facilities located in the United States (23), North America (5), Europe (20), Africa and Asia/Pacific (13). The United States accounts for 54.5% of net sales.
Employees
1,31,900
Sector
Pharmaceuticals
Calendar
22/01/2025 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
06/24/06 149.68 $ +0.10% 403,618
05/24/05 149.52 $ -0.63% 7,898,098
04/24/04 150.47 $ -1.24% 10,333,110
03/24/03 152.36 $ -1.58% 8,674,415
02/24/02 154.80 $ -0.14% 6,946,494

Delayed Quote Nyse, December 06, 2024 at 02:30 am IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart JOHNSON-JOHNSON More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart JOHNSON-JOHNSONMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
149.52USD
Average target price
174.89USD
Spread / Average Target
+16.97%
Consensus
Profit revisions
estimates-change-chart JOHNSON-JOHNSON Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart JOHNSON-JOHNSON Company calendar
  1. Stock Market
  2. Equities
  3. JNJ Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition